Show simple item record

dc.contributor.authorChan, Arlene
dc.identifier.citationChan, A. 2016. Neratinib in HER-2-positive breast cancer: Results to date and clinical usefulness. Therapeutic Advances in Medical Oncology. 8 (5): pp. 339-350.

© The Author(s), 2016.The management of HER-2-positive breast cancer has improved significantly with the use of targeted agents to the HER-2 signaling pathway. Despite the improved survival achieved with the use of trastuzumab and chemotherapy in both the adjuvant and metastatic setting, patients may still recur or progress; whilst preclinical data demonstrate that these cancer cells remain addicted to the HER-2 oncogene. Neratinib, an oral small molecule tyrosine-kinase inhibitor has efficacy in the metastatic and adjuvant setting of patients who have previously received trastuzumab-based treatment. Diarrhea, being a class effect of tyrosine-kinase inhibitor, is the most common side effect seen following neratinib administration, but recent data suggests that a prophylactic loperamide regimen can reduce the incidence of grade 3 diarrhea. Phase I through to III clinical trials of neratinib will be reviewed, with discussion of the postulated mechanism underlying diarrheal events and its management.

dc.titleNeratinib in HER-2-positive breast cancer: Results to date and clinical usefulness
dc.typeJournal Article
dcterms.source.titleTherapeutic Advances in Medical Oncology
curtin.departmentCurtin Medical School
curtin.accessStatusOpen access via publisher

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record